Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Phase 2 (NA-931, 13 weeks): Key characteristics: Lowest GI adverse event rates of any drug in this comparison by a wide margin 83% of all GI events classified as "insignificant" No clinically meaningful difference in GI events between NA-931 and placebo No muscle loss observed However, the study was only 13 weeks with 125 participants -- tolerability at higher doses and longer durations is unknown Side-by-Side Comparison# NR = not reported
X.Y.Y., L.S., L.Q.Q
Until then, retatrutide appears more potent but tirzepatide is proven, approved, and available now via the tirzepatide dosage chart in units
In March 2023, WW purchased Sequence, a subscription telehealth platform specializing in medical weight management, to prescribe GLP-1s and launch an associated support program
US$ 20.85
US$ 22.94
US$ 29.65
